Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in previously treated KRAS G12C-mutant non-small-cell lung cancer
KCT0007591Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Exploratory analysis (ctDNA). Started Oct 2022; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0007591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007591.